"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
Zn-DTPA Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Zn-DTPA (pentetate zinc trisodium) Injection is a chelating agent used to treat patients with known or suspected internal contamination with plutonium, americium, or curium to increase the rates of elimination. Common side effects include headache, lightheadedness, and pelvic pain.
The dose of Zn-DTPA for adults and adolescent is a single 1.0 gram initial dose administered intravenously. The pediatric dose (less than 12 years of age) is a single initial dose of 14 mg/kg administered intravenously not to exceed 1.0 gram. Zn-DTPA may interact with other drugs. Tell your doctor all medications and supplements you use. During pregnancy, Zn-DTPA should be used only if prescribed. Radiocontaminants are known to pass into breast milk. Women with known or suspected internal contamination with radiocontaminants should not breastfeed, whether or not they are receiving chelation therapy. Precautions should be taken when discarding breast milk.
Our Zn-DTPA (pentetate zinc trisodium) Injection Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Zn-DTPA FDA Prescribing Information: Side Effects
In the U.S. Registry, a total of 646 individuals received at least one dose of either Ca-DTPA or Zn-DTPA (pentetate zinc trisodium injection) . Of these, 62 received Zn-DTPA (pentetate zinc trisodium injection) by one or more routes of administration. Forty-eight individuals were dosed by intravenous administration, 18 by inhalation and 8 by other or unknown routes of administration.
Of the individuals that received Zn-DTPA (pentetate zinc trisodium injection) , 23/62 (37%) received one dose and 8 (13%) received two doses. The remaining 31 individuals received three or more doses. The largest number of Zn-DTPA (pentetate zinc trisodium injection) doses to a single individual was 574 doses delivered over 3.5 years.
Overall, the presence or absence of adverse events was recorded in 310/646 individuals. Of these 19 (6.1%) individuals reported at least one adverse event. The total number of recorded adverse events was 20. Of the 20 adverse events, 1 individual treated with Zn-DTPA (pentetate zinc trisodium injection) reported headache, lightheadedness, and pelvic pain.
Read the entire FDA prescribing information for Zn-DTPA (Pentetate Zinc Trisodium Injection) »
Additional Zn-DTPA Information
Report Problems to the Food and Drug Administration
Find out what women really need.